Want to see FR:ALMDT full AI Analyst Report?
Median Technologies (ALMDT) AI Stock Analysis
Top Page
Median Technologies
(Paris:ALMDT)
The score is held down primarily by weak financial performance—large ongoing losses, negative cash flow, and negative equity—despite revenue growth. Technicals add further pressure with the price below key moving averages, while valuation is difficult to justify positively given the negative P/E and lack of dividend data.
Median Technologies (ALMDT) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 180.85M
- Dividend Yield
- ―
- Average Volume (3M)
- 145.96K
- Price to Earnings (P/E)
- -3.0
- Beta (1Y)
- 0.93
- Revenue Growth
- 2.16%
- EPS Growth
- -5.26%
- Country
- France
- Employees
- 199
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Median Technologies Business Overview & Revenue Model
Company Description
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving m...
How the Company Makes Money
Median Technologies primarily makes money through (1) imaging services and software provided to biopharmaceutical companies and clinical research organizations to support oncology drug development and clinical trials, and (2) commercialization of its...
Median Technologies Financial Statement Overview
Summary
Financial health is weak despite improved revenue growth. The company remains deeply loss-making with sharply negative gross profit in 2024–2025, persistent negative operating cash flow (ongoing cash burn), and a strained capital structure with negative equity in recent years—raising financing/dilution risk.
Income Statement
18Very NegativeBalance Sheet
22NegativeCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.82M | 23.36M | 22.95M | 22.23M | 23.67M | 20.55M |
| Gross Profit | 16.50M | 24.05M | -21.07M | -2.55M | 24.42M | 20.43M |
| EBITDA | -23.95M | -25.13M | -19.28M | -19.35M | -17.39M | -16.98M |
| Net Income | -51.80M | -34.07M | -25.24M | -22.98M | -20.21M | -19.29M |
Balance Sheet | ||||||
| Total Assets | 77.83M | 35.87M | 24.37M | 35.94M | 34.75M | 49.39M |
| Cash, Cash Equivalents and Short-Term Investments | 60.83M | 18.41M | 8.29M | 19.63M | 21.67M | 39.25M |
| Total Debt | 26.12M | 21.76M | 29.44M | 23.01M | 18.15M | 16.52M |
| Total Liabilities | 80.81M | 71.02M | 58.34M | 46.23M | 42.01M | 44.45M |
| Stockholders Equity | -2.99M | -35.15M | -33.97M | -10.29M | -7.25M | 4.94M |
Cash Flow | ||||||
| Free Cash Flow | -10.58M | -18.17M | -19.03M | -21.53M | -17.18M | -10.61M |
| Operating Cash Flow | -19.63M | -17.43M | -17.95M | -20.24M | -15.79M | -10.13M |
| Investing Cash Flow | -1.12M | -824.00K | -1.17M | -1.25M | -1.39M | -672.00K |
| Financing Cash Flow | 77.06M | 28.43M | 7.67M | 19.72M | -277.00K | 33.20M |
Median Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMDT, the sentiment is Negative. The current price of 3.69 is below the 20-day moving average (MA) of 3.91, below the 50-day MA of 3.96, and below the 200-day MA of 4.58, indicating a bearish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 42.29 is Neutral, neither overbought nor oversold. The STOCH value of 48.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMDT.
Median Technologies Peers Comparison
Overall Rating
FR:ALERS58Neutral
FR:ALIKO46Neutral
FR:ALTHE46Neutral
FR:ALMKT45Neutral- FR:ALMDT43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:ALERS | 58Neutral | EUR 258.39M | 37.57 | 3.89% | ― | 6.28% | 204.56% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:ALIKO | 46Neutral | EUR 22.42M | -5.20 | -22.03% | ― | 37.28% | 7.83% |
| FR:ALTHE | 46Neutral | EUR 51.65M | -6.76 | 453.10% | ― | -16.98% | 20.31% |
| FR:ALMKT | 45Neutral | EUR 18.94M | 1.53 | -157.72% | ― | 3.38% | ― |
| FR:ALMDT | 43Neutral | EUR 180.85M | -3.00 | 271.64% | ― | 2.16% | -5.26% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALMDT | Median Technologies | 3.69 | 0.79 | 27.24% | |
| FR:ALMKT | MAUNA KEA TECHNOLOGIES | 0.10 | -0.00 | -1.02% | |
| FR:ALTHE | Theraclion SA | 0.70 | 0.05 | 7.69% | |
| FR:ALERS | Eurobio-Scientific SA | 26.30 | 2.15 | 8.90% | |
| FR:ALDMS | Diagnostic Medical Systems | 0.91 | -0.41 | -30.95% | |
| FR:ALIKO | Ikonisys SA | 1.42 | -0.04 | -2.74% |
Median Technologies Corporate Events
Median Technologies posts record iCRO quarter as it ramps up U.S. launch of AI lung cancer tool
Median Technologies reported a record third-quarter 2026 performance in its iCRO imaging services arm, with revenue rising 14.4% year-on-year to €6.7 million and the order book reaching €90.9 million, underpinned by strong demand from bio...
Median Technologies to Highlight AI Imaging Capabilities at ESMO 2026
Median Technologies will showcase its latest AI-driven central imaging and image analysis capabilities for oncology trials at the ESMO Congress 2026 in Madrid, underscoring its role as a technology partner for cancer drug developers. The company̵...
Median Technologies Showcases FDA-Cleared AI Lung Screening Tool at I-ELCAP Conference
Median Technologies and its U.S. subsidiary eyonis Inc. will showcase their AI-powered lung cancer screening software, eyonis LCS, at the 50th International Conference on Lung Cancer Screening organized by I-ELCAP in New York in October 2026. The eve...
Median Technologies Targets U.S. Lung Cancer Screening Market With High-Performing AI Software at CHEST 2026
Median Technologies’ U.S. subsidiary Eyonis Inc. will showcase its FDA-cleared eyonis LCS software at the CHEST 2026 congress in Phoenix, targeting pulmonologists who are central to lung cancer screening program adoption. The company aims to de...
Median Technologies Updates Share Capital and Warrants Status
Median Technologies has reported updated share capital and voting rights figures, confirming a total of 49,071,263 shares and 48,998,813 actual voting rights as of September 30, 2026. The disclosure, made under French commercial and market regulation...
Median Technologies Wins €8.4 Million Global Phase III Brain Cancer Imaging Contract
Median Technologies has secured one of the largest contracts in its history, a €8.4 million global phase III oncology project awarded by a leading European pharmaceutical group for a rare and complex brain cancer trial. The deal will see Median...
Median Technologies sets H1 2026 earnings date and intensifies investor outreach
Median Technologies has outlined its upcoming financial communication schedule, stating that its H1 2026 results will be released after market close on October 29, 2026. The announcement provides investors with visibility on the next key financial re...
Median Technologies Updates Capital Structure and Outstanding Warrants
Median Technologies disclosed updated capital and voting rights data, reporting a share capital composed of 49,071,263 shares and an actual voting rights count of 49,002,485, alongside a theoretical voting rights total of 49,048,063. The company also...
Median Technologies launches strategic review to unlock value in AI oncology businesses
Median Technologies’ board has launched a Strategic Review Committee to examine structural, transactional and financing options, including a possible separation of its iCRO unit from the eyonis® medical device business and a potential U.S....
Median Technologies Updates Share Capital and Warrants in Regulatory Filing
Median Technologies has disclosed its latest capital structure and voting rights data, reporting a total of 49,071,263 shares outstanding. The company lists 49,011,540 real voting rights, with a slightly higher theoretical voting rights figure that i...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026